NMDAR inhibition-independent antidepressant actions of ketamine metabolites

Nature

Volumn 533, Issue 7604, 2016, Pages 481-486

  Zanos, Panos ^a   Moaddel, Ruin ^b   Morris, Patrick J ^c   Georgiou, Polymnia ^a   Fischell, Jonathan ^a   Elmer, Greg I ^a,d   Alkondon, Manickavasagom ^a   Yuan, Peixiong ^e   Pribut, Heather J ^a   Singh, Nagendra S ^b   Dossou, Katina S S ^b   Fang, Yuhong ^c   Huang, Xi Ping ^f   Mayo, Cheryl L ^d   Wainer, Irving W ^b   Albuquerque, Edson X ^a   Thompson, Scott M ^a   Thomas, Craig J ^c   Zarate, Carlos A ^e   Gould, Todd D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ANTIDEPRESSANT AGENT; DESIPRAMINE; DRUG METABOLITE; GLUTAMIC ACID; HYDROXYNORKETAMINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; 6-HYDROXYNORKETAMINE; AMPA RECEPTOR;

DISEASE TREATMENT; DRUG; DRUG DEVELOPMENT; INHIBITION; MENTAL HEALTH; METABOLISM; METABOLITE; PHYSIOLOGICAL RESPONSE; PROTEIN; RODENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DOSE; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; ELECTROENCEPHALOGRAPHY; ENANTIOMER; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; HIPPOCAMPUS; HUMAN; INTERNEURON; LEARNED HELPLESSNESS TEST; LOCOMOTION; MALE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; SIDE EFFECT; SYNAPTIC TRANSMISSION; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; TIME FACTOR;

MUS;

ANIMALS; ANTIDEPRESSIVE AGENTS; FEMALE; KETAMINE; MALE; MICE; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS;

EID: 84969672767     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature17998     Document Type: Article

References (39)

1. Kessler, R.C. et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289, 3095-3105 (2003).
2. Trivedi, M. H. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR D: implications for clinical practice. Am. J. Psychiatry 163, 28-40 (2006).
3. Rush, A. J. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am. J. Psychiatry 163, 1905-1917 (2006).
4. Zarate, C. A., Jr et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856-864 (2006).
5. Berman, R. M. et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47, 351-354 (2000).
6. Diazgranados, N. et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67, 793-802 (2010).
7. Lally, N. et al. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl. Psychiatry 4, e469 (2014).
8. Murrough, J. W. et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry 170, 1134-1142 (2013).
9. Morgan, C. J., Curran, H. V. Ketamine use: a review. Addiction 107, 27-38 (2012).
10. Newport, D. J. et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am. J. Psychiatry 172, 950-966 (2015).
11. Leung, L. Y., Baillie, T. A. Comparative pharmacology in the rat of ketamine and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J. Med. Chem. 29, 2396-2399 (1986).
12. Moaddel, R. et al. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in ?7 nicotinic acetylcholine receptors. Eur. J. Pharmacol. 698, 228-234 (2013).
13. Ebert, B., Mikkelsen, S., Thorkildsen, C., Borgbjerg, F. M. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur. J. Pharmacol. 333, 99-104 (1997).
14. Yang, C. et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl. Psychiatry 5, e632 (2015).
15. Maeng, S. et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of ?-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol. Psychiatry 63, 349-352 (2008).
16. Autry, A. E. et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91-95 (2011).
17. Desta, Z. et al. Stereoselective and regiospecific hydroxylation of ketamine and norketamine. Xenobiotica 42, 1076-1087 (2012).
18. Adams, J. D., Jr, Baillie, T. A., Trevor, A. J., Castagnoli, N. Jr. Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed. Mass Spectrom. 8, 527-538 (1981).
19. Zarate, C. A., Jr et al. Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol. Psychiatry 72, 331-338 (2012).
20. Carrier, N., Kabbaj, M. Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology 70, 27-34 (2013).
21. Franceschelli, A., Sens, J., Herchick, S., Thelen, C., Pitychoutis, P. M. Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naive and "depressed" mice exposed to chronic mild stress. Neuroscience 290, 49-60 (2015).
22. Irifune, M., Shimizu, T., Nomoto, M., Fukuda, T. Involvement of N-methyl-daspartate (NMDA) receptors in noncompetitive NMDA receptor antagonistinduced hyperlocomotion in mice. Pharmacol. Biochem. Behav. 51, 291-296 (1995).
23. Gant, T. G. Using deuterium in drug discovery: leaving the label in the drug. J. Med. Chem. 57, 3595-3611 (2014).
24. Duman, R. S., Aghajanian, G. K., Sanacora, G., Krystal, J. H. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nature Med. 22, 238-249 (2016).
25. Li, N. et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964 (2010).
26. Koike, H., Iijima, M., Chaki, S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav. Brain Res. 224, 107-111 (2011).
27. Koike, H., Chaki, S. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav. Brain Res. 271, 111-115 (2014).
28. Whittington, M. A., Traub, R. D., Kopell, N., Ermentrout, B., Buhl, E. H. Inhibition-based rhythms: experimental and mathematical observations on network dynamics. Int. J. Psychophysiol. 38, 315-336 (2000).
29. Cunningham, M. O., Davies, C. H., Buhl, E. H., Kopell, N., Whittington, M. A. Gamma oscillations induced by kainate receptor activation in the entorhinal cortex in vitro. J. Neurosci. 23, 9761-9769 (2003).
30. Muthukumaraswamy, S. D. et al. Evidence that Subanesthetic doses of ketamine cause sustained disruptions of NMDA and AMPA-mediated frontoparietal connectivity in humans. J. Neurosci. 35, 11694-11706 (2015).
31. Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., Duman, R. S. BDNF release is required for the behavioral actions of ketamine. Int. J. Neuropsychopharmacol. 18, pyu033 (2015).
32. De Vry, J., Jentzsch, K. R. Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. Behav. Pharmacol. 14, 229-235 (2003).
33. Moaddel, R. et al. The distribution and clearance of (2S,6S)-hydroxynorketamine, an active ketamine metabolite, in Wistar rats. Pharmacol. Res. Perspect. 3, e00157 (2015).
34. Donahue, R. J., Muschamp, J. W., Russo, S. J., Nestler, E. J., Carlezon, W. A. Jr. Effects of striatal ?FosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol. Psychiatry 76, 550-558 (2014).
35. Malkesman, O. et al. The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biol. Psychiatry 67, 864-871 (2010).
36. Zanos, P. et al. The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineb-site inhibition. J. Pharmacol. Exp. Ther. 355, 76-85 (2015).
37. Chiu, J. et al. Chronic ethanol exposure alters MK-801 binding sites in the cerebral cortex of the near-term fetal guinea pig. Alcohol 17, 215-221 (1999).
38. Raver, S. M., Haughwout, S. P., Keller, A. Adolescent cannabinoid exposure permanently suppresses cortical oscillations in adult mice. Neuropsychopharmacology 38, 2338-2347 (2013).
39. Bokil, H., Andrews, P., Kulkarni, J. E., Mehta, S., Mitra, P. P. Chronux: a platform for analyzing neural signals. J. Neurosci. Methods 192, 146-151 (2010).